No Data
No Data
Huiray Biotechnology (300942.SZ): The company does not rule out enhancing its competitiveness through mergers and acquisitions in the future.
On December 4th, GELONGHUI reported that Eryi Biological (300942.SZ) stated during an investor relations event that from a global strategy perspective, the company does not rule out enhancing competitiveness through mergers and acquisitions, bringing value-added effects to the company and creating more value for shareholders.
Yirui Biological (300942.SZ): The company has the testing capability for pre-cooked food related products.
Gelonghui, on November 29, reported that Yirui Biological (300942.SZ) stated on the investor interaction platform that the company has the testing capability for pre-cooked food related products, which can achieve high-precision testing for various limited substances including preservatives, veterinary drug residues, pesticide residues, mycotoxins, and pathogenic microorganisms, effectively ensuring food safety.
Is Shenzhen Bioeasy Biotechnology (SZSE:300942) Using Too Much Debt?
Yirui Biology (300942.SZ): The fully automated testing workstation developed has multiple customers currently progressing in the project.
On October 31, Equity Press reported that Yirui Biology (300942.SZ) stated at an investor relations event that the company has developed a fully automated detection workstation. Currently, multiple customers are progressing with the project, such as some factories of Mengniu have completed validation, and Qingdao Nestle have completed validation and are in the trial phase. Several customers like guangdong yantang dairy have expressed purchasing intentions and are in discussions. The company provides customers with systematic and digital solutions, ensuring the quality of detection, assisting customers in achieving digital transformation of quality control and traceability, cost reduction, and efficiency improvement. Additionally, considering the compatibility of test reagents, the sales of fully automated detection workstations will continue.
Yirui Biotech: Report for the third quarter of 2024
Optimistic Investors Push Shenzhen Bioeasy Biotechnology Co., Ltd. (SZSE:300942) Shares Up 46% But Growth Is Lacking